United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M
United Therapeutics has acquired Thymmune Therapeutics for $140 million, a move that aligns with United Therapeutics' mission to enhance organ health and transplants. The acquisition occurred shortly after United Therapeutics received FDA premarket approval for a lung transplant drug, highlighting the company's focus on innovative medical solutions.
Thymmune Therapeutics acquired by Maryland biotech for $140M
Thymmune Therapeutics has been acquired by United Therapeutics for $140 million. This acquisition, which closed on Thursday, integrates Thymmune's thymus cell therapy platform with United Therapeutics' focus on lung disease treatments and pig-to-human transplant research. The deal was reported by the Washington Business Journal.
United Therapeutics acquires Thymmune for $140 million
United Therapeutics (NASDAQ:UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential additional milestone payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies for immune-related diseases, including THY-100 for congenital athymia. This acquisition is set to bolster United Therapeutics' efforts in organ alternatives and immunomodulatory treatments, aligning with its strategy to expand regenerative medicine capabilities.
United Therapeutics buys Thymmune, adding thymus cell therapy platform
United Therapeutics (NASDAQ: UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies derived from induced pluripotent stem cells (iPSC), aimed at treating conditions like post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. This acquisition strengthens United Therapeutics' focus on expanding transplantable organ supply and immunomodulatory therapeutics.
United Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $300 million.
United Therapeutics Corporation (NasdaqGS:UTHR) has acquired Thymmune Therapeutics, Inc. for a total consideration of $300 million. The acquisition includes an upfront payment of $140 million in cash, with an additional potential $160 million in earn-out payments tied to clinical and regulatory milestones by the end of 2031. The deal was finalized on July 2, 2026.
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold 9,500 shares of the company’s common stock for approximately $5.18 million. This transaction followed the exercise of stock options and was conducted under a pre-arranged 10b5-1 trading plan. Despite the insider sale, United Therapeutics maintains a "GREAT" financial health score, holding more cash than debt and boasting an 87% gross profit margin.
The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026
The Oliver Patch Project has announced that United Therapeutics Corporation will be the Visionary/Presenting Sponsor for National Patch Day 2026. This initiative aims to spread hope and encouragement to children, teens, and young adults nationwide who are facing cancer, serious illnesses, disabilities, and mental health challenges. National Patch Day operates year-round, distributing over 100,000 patches globally to foster kindness, strength, and connection.
United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 9,500 shares for approximately $5.18 million after exercising stock options under a pre-arranged 10b5-1 trading plan. Following the sale, Rothblatt holds various direct and indirect shares and options. Despite the insider sale, United Therapeutics maintains a strong financial health score and has recently received FDA approval for its LungFX device, delivered positive results for its TETON-1 study, and formed a partnership with Varda Space Industries.
United Therapeutics Insider Sold Shares Worth $5,167,734, According to a Recent SEC Filing
An insider at United Therapeutics Corporation recently sold shares totaling $5,167,734, as disclosed in a recent SEC filing. The article, however, is reserved for members only, requiring registration to access the full details of the transaction. United Therapeutics develops and commercializes therapies for pulmonary arterial hypertension and other conditions.
FDA Approves United Therapeutics’ LungFX For Centralized Lung Perfusion, On A Narrow Indication
The FDA has approved United Therapeutics' LungFX for centralized lung perfusion. The approval is specifically for a narrow indication, highlighting the targeted application of this medical device. This development is significant for the field of respiratory medicine.
United Therapeutics receives FDA approval for LungFX EVLP device
United Therapeutics (NASDAQ:UTHR) has received FDA premarket approval for its LungFX device, designed for centralized ex vivo lung perfusion (EVLP). This device allows for the assessment of donor lungs outside the body, with the potential to significantly increase the number of organs available for transplantation. United Therapeutics' subsidiary, Lung Bioengineering, has a track record of performing over 1,100 EVLP procedures, leading to 600 successful lung transplants, and plans to integrate LungFX into its services by 2027.
FDA approves United Therapeutics' LungFX to assess donor lungs
United Therapeutics (NASDAQ: UTHR) announced that its LungFX device has received Premarket Approval (PMA) from the FDA for centralized ex vivo lung perfusion (EVLP). This approval makes LungFX the first device cleared for assessing donor lungs outside the body, especially those not initially used for transplant, aiming to significantly increase the number of transplantable organs. United Therapeutics' subsidiary, Lung Bioengineering Inc., plans to integrate LungFX into its services by 2027, building on its experience with over 1,100 EVLP procedures.
United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 2500 Value Benchmark
United Therapeutics Corporation (NasdaqGS: UTHR) has been removed from the Russell 2500 Value Benchmark Index. This news follows several insider share sales, with transactions reported throughout June 2026. The company recently received FDA premarket approval for its LungFX Device and announced its presentation at the Jefferies Global Healthcare Conference 2026.
Enterprise value to revenue forward of United Therapeutics Corporation – NASDAQ:UTHR
This article focuses on the "Enterprise value to revenue forward" metric for United Therapeutics Corporation (NASDAQ: UTHR). The content is primarily a data placeholder from TradingView, indicating a financial analysis product rather than a detailed report. It mentions accessing financial data for UTHR on the TradingView platform.
Price to earnings forward of United Therapeutics Corporation – NASDAQ:UTHR
This article focuses on the "Price to earnings forward" metric for United Therapeutics Corporation (NASDAQ: UTHR). It presents a financial data point for the company within the context of the Biotechnology sector, indicating market closure at the time of publication without active trades.
Price to sales forward of United Therapeutics Corporation – NASDAQ:UTHR
This article provides financial data for United Therapeutics Corporation (NASDAQ: UTHR), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a data-driven page, presenting the company's stock information and financial metrics within the TradingView platform.
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares By Investing.com
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, sold 9,500 shares of company stock worth approximately $5.2 million on June 25, 2026, under a pre-arranged 10b5-1 trading plan. On the same day, she also acquired 9,500 shares by exercising stock options at a lower price. This sale comes as the company's shares have surged, and follows recent news of a successful Phase 3 study for Tyvaso and a partnership with Varda Space Industries.
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares amounting to approximately $5.2 million, executed under a pre-arranged 10b5-1 trading plan. Despite a significant share surge over the past year, InvestingPro's analysis suggests the stock is currently overvalued. Concurrently, Rothblatt exercised stock options to acquire 9,500 shares, increasing her direct and indirect holdings in the company.
United Therapeutics (UTHR) TD Cowen 46th Annual Health Care Conference Summary
United Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, highlighting continued double-digit growth in its commercial business and the anticipated launch of Ralinepag for PAH and Tyvaso for IPF as best-in-class therapies. Ralinepag showed significant clinical benefits for PAH patients, including a 55% reduction in risk of clinical worsening, and is projected to achieve up to $2 billion in annual sales by 2030. The company also announced a new soft mist inhaler for inhaled therapies, expected to reduce cough and become the preferred delivery option.
United Therapeutics CEO Martine Rothblatt sells $5.2m in shares
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares of the company's common stock for approximately $5.2 million on June 25, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan. Despite the stock's 91% surge in the past year, InvestingPro analysis suggests it is currently overvalued.
Form 4 United Therapeutics Corporation For: 26 June By Investing.com
This article reports on a Form 4 filing for United Therapeutics Corporation related to June 26. It is a brief corporate financial news item provided by Investing.com, accompanied by various market data. The article mentions the stock symbol UTHR and gives current market indices, commodity prices, and bond yields.
United Therapeutics (UTHR) AGM 2026 Summary
United Therapeutics held its virtual 2026 Annual General Meeting (AGM) on June 26, 2026, marking the company's 30th anniversary. The meeting included the introduction of 12 director nominees for election, updates on governance, and voting on four key proposals: director elections, executive compensation approval, a 2026 Stock Incentive Plan, and ratification of the independent auditor, all of which the board recommended approving. The article also provides a summary of recent company events, including clinical results, financial reports, and other conference presentations.
United Therapeutics Corporation Actuals & Estimates (DUS:UTH)
This article provides an overview of United Therapeutics Corporation (UTH) stock, including financial actuals and analyst estimates. Key information covers stock tickers, price forecasts with maximum and minimum estimates, historical price dynamics, upcoming earnings dates, past earnings and revenue figures, net income, dividend policy (no dividends), employee count, and EBITDA. The article also explains how to buy UTH stocks through online brokers.
United Therapeutics Corporation Actuals & Estimates (BMV:UTHR)
This article provides an overview of United Therapeutics Corporation (BMV: UTHR) stock, including current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial results such as revenue and net income. Investors are advised to conduct thorough research before making investment decisions.
Martine A. Rothblatt sells $5.2m United Therapeutics shares By Investing.com
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, sold 9,500 shares of common stock for over $5.2 million on June 24, 2026, after acquiring them through stock option exercises. The transactions were pre-arranged under a 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high and considered overvalued by InvestingPro.
Martine A. Rothblatt sells $5.2m United Therapeutics shares
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, sold 9,500 shares of common stock for over $5.2 million on June 24, 2026, after exercising stock options. These transactions were part of a pre-arranged 10b5-1 trading plan. Despite the sale, management's aggressive share buybacks and the company's progress in clinical trials are highlighted.
United Therapeutics chairperson & CEO sells $5.17m in stock By Investing.com
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp., sold 9,500 shares for over $5.1 million, acquired through stock option exercises. The transactions were pre-arranged under a 10b5-1 trading plan. The company's stock has seen an 88% surge over the past year, though InvestingPro analysis suggests it may be overvalued.
Form 4 United Therapeutics Corporation For: 25 June By Investing.com
This article reports on a Form 4 filing for United Therapeutics Corporation (UTHR) for June 25, 2026. The brief piece indicates that UTHR experienced a -0.44% change according to Investing.com. The content primarily serves as an announcement for the filing rather than detailed analysis.
United Therapeutics (UTHR) Is More Than a Single-Drug Biotech Because Cash Flow Funds a Broader Transplant Platform
United Therapeutics (UTHR) is often perceived as a single-drug biotech due to its dominant Tyvaso franchise, but this view is incomplete. The company uses its significant cash flow from its cardiopulmonary business to fund a broader platform, including next-wave therapies, drug-delivery innovation, and a long-horizon organ-manufacturing effort. This strategy provides both concentration risk and significant optionality, positioning UTHR beyond a typical one-asset biotech.
United Therapeutics (UTHR) Could Be 17% Below Fair Value As First Quarter Miss Shakes Confidence
United Therapeutics (UTHR) recently reported a weak first quarter with lower revenue and an earnings miss, causing investor confidence to waver despite strong longer-term performance. While a narrative fair value suggests the stock is 17.3% undervalued, this relies on future growth through its innovation pipeline in pulmonary and organ manufacturing, which also carries risks. The company's P/E ratio is currently above the US biotech industry average, prompting questions about its future re-rating or de-rating.
United Therapeutics chairperson & CEO sells $5.17m in stock
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp., sold 9,500 shares of company stock worth $5.17 million on June 23, 2026, as part of a pre-arranged 10b5-1 trading plan. These sales followed an exercise of stock options and occurred after the company's shares surged 88% over the past year. The article also notes recent company news, including positive Phase 3 study results for Tyvaso, first-quarter revenue falling short of estimates, and collaborations for microgravity-based pharmaceutical processing.
United Therapeutics chairperson & CEO sells $5.17m in stock By Investing.com
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp. (NASDAQ: UTHR), sold 9,500 shares for over $5.17 million. These sales were part of a pre-arranged 10b5-1 trading plan after the company's stock surged 88% over the past year. Rothblatt still holds substantial direct and indirect shares and stock options in the company.
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ: UTHR), sold 9,500 shares for over $5.1 million on June 22, 2026, as part of a pre-arranged 10b5-1 trading plan. This followed the exercise of stock options to acquire the same number of shares. InvestingPro analysis suggests the stock might be overvalued despite impressive past performance.
United Therapeutics CEO Rothblatt sells $5.1m in UTHR shares By Investing.com
United Therapeutics CEO Martine A. Rothblatt sold approximately $5.1 million worth of UTHR shares on June 22, 2026, as part of a pre-arranged 10b5-1 trading plan. She acquired 9,500 shares through option exercises before selling them. The company recently reported first-quarter revenue and net income below analyst expectations, though its TETON-1 phase 3 study met its primary endpoint and it partnered with Varda Space Industries for pharmaceutical processing.
Form 4 United Therapeutics Corporation For: 24 June By Investing.com
This article announces a Form 4 filing for United Therapeutics Corporation on June 24th. Form 4 filings report changes in beneficial ownership of company stock by insiders. The brief news item includes the stock symbol UTHR, which saw a slight increase of 0.68%.
United Therapeutics Insider Sold Shares Worth $5,401,489, According to a Recent SEC Filing
An insider at United Therapeutics Corporation sold shares valued at $5,401,489, as disclosed in a recent SEC filing. This event is part of a series of insider share disposals reported by MT Newswires, highlighting consistent selling activity. United Therapeutics (UTHR) is a pharmaceutical company specializing in treatments for pulmonary arterial hypertension and an oncology product.
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold $5.13 million worth of common stock on June 18, 2026, after exercising stock options for $1.39 million on the same day. These transactions were executed under a pre-arranged 10b5-1 trading plan. The article also mentions the company's recent positive phase 3 study results for nebulized Tyvaso, a first-quarter revenue miss, and a collaboration with Varda Space Industries, alongside varied analyst ratings.
Form 4 United Therapeutics Corporation For: 22 June By Investing.com
This article is a Form 4 filing for United Therapeutics Corporation (UTHR) for June 22. Form 4 filings are regulatory documents that insider traders must submit to the SEC when they trade securities of their own company. The article originates from Investing.com.
United Therapeutics EVP Mahon sells $4.5m in company stock
Paul A. Mahon, Executive Vice President and General Counsel at United Therapeutics Corp, sold 8,300 shares of company stock worth approximately $4.5 million on June 18, 2026, after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan established in August 2025. The sale follows an 89% return on the stock over the past year, though InvestingPro analysis suggests it may be overvalued.
United Therapeutics CEO Rothblatt sells $5.2m in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.22 million in common stock through a pre-arranged trading plan, while simultaneously acquiring shares by exercising stock options as part of the same plan. Following these transactions, Rothblatt retains significant direct and indirect holdings in the company. The company also recently announced positive phase 3 study results for nebulized Tyvaso and reported first-quarter earnings, leading to varying analyst ratings.
United Therapeutics EVP Mahon sells $4.5m in company stock By Investing.com
Paul A. Mahon, EVP and General Counsel at United Therapeutics Corp (NASDAQ:UTHR), sold 8,300 shares worth $4.5 million on June 18, 2026, after exercising stock options. These transactions were pre-arranged under a 10b5-1 trading plan. The sale follows an impressive 89% stock return over the past year, though the company recently missed first-quarter revenue and net income estimates.
United Therapeutics EVP Mahon sells $4.5m in company stock
Paul A. Mahon, EVP and General Counsel at United Therapeutics Corp, sold 8,300 shares worth approximately $4.5 million on June 18, 2026, after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. The sale follows a significant 89% return for United Therapeutics stock over the past year and comes amidst recent company news including positive phase 3 study results for nebulized Tyvaso and a partnership with Varda Space Industries, despite first-quarter revenues missing consensus estimates.
United Therapeutics CEO Rothblatt sells $5.2m in shares
United Therapeutics CEO Martine A. Rothblatt sold approximately $5.22 million worth of company stock on June 16, 2026, as part of a pre-arranged 10b5-1 trading plan. Concurrently, she acquired shares through stock option exercises. The transactions follow the company's recent announcement of a successful Phase 3 study for nebulized Tyvaso and mixed financial results for the first quarter.
United Therapeutics' Liver Assist Product Earns FDA Regenerative Medicine Advanced Therapy Designation
United Therapeutics Corporation's investigational external liver assist product, miroliver ELAP, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation aims to accelerate the development and regulatory review of promising regenerative medicine therapies for serious or life-threatening diseases, highlighting the critical unmet need for treatments for acute liver failure. Miroliver ELAP provides temporary liver support using a bioengineered liver and is currently in clinical development, with positive phase 1 results already announced.
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold approximately $5.14 million in common stock on June 12, 2026, as part of a pre-arranged 10b5-1 trading plan. Concurrently, she exercised stock options worth about $1.39 million. These transactions follow the company's recent first-quarter results which missed analyst expectations, despite positive developments like a successful TETON-1 study and a collaboration with Varda Space Industries.
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com
United Therapeutics CFO James Edgemond sold 10,000 shares of the company's common stock for $5.49 million on June 11, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he exercised stock options to acquire the same number of shares. The company, trading at $545.96 with a $23.1 billion market cap, recently reported mixed Q1 results but announced positive Phase 3 study results for nab-Tyvaso and a partnership with Varda Space Industries.
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com
James Edgemond, CFO of United Therapeutics Corp, sold 10,000 shares of company stock for approximately $5.49 million, executed under a Rule 10b5-1 trading plan. These sales occurred concurrently with the exercise of stock options. Despite the sale, Edgemond directly holds 18,876 shares, and the company recently reported first-quarter revenue below consensus but also announced positive phase 3 study results for its nebulized Tyvaso.
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com
United Therapeutics (NASDAQ: UTHR) CFO James Edgemond sold 10,000 shares of the company's common stock for approximately $5.49 million on June 11, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred concurrently with the exercise of stock options. Despite the sale, Edgemond still holds 18,876 shares, and the company has strong fundamentals, although InvestingPro identifies the stock as overvalued.
United Therapeutics CFO Edgemond sells $5.49m in company stock
United Therapeutics Corp CFO and Treasurer James Edgemond sold 10,000 shares of company stock for over $5.49 million on June 11, 2026. This transaction was part of a pre-arranged trading plan, executed concurrently with the exercise of stock options. The company's stock has seen a 91% return over the past year, though InvestingPro analysis suggests it may be overvalued.
Neuroblastoma Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Y-mAbs Therapeutics, United Therapeutics Corp, EUSA Pharma, Clarity Pharma, Eli Lilly
The neuroblastoma market is projected to grow significantly by 2034, driven by an expanding pipeline of therapies and increasing investment. Key market players, including Y-mAbs Therapeutics, United Therapeutics Corp, and Eli Lilly, are advancing various treatments, with developments like EMA applications for eflornithine and continued progress in GD2-targeted immunotherapies. The market's growth is also supported by increasing awareness, improved diagnostic techniques, and advancements in targeted therapies, despite challenges like high treatment toxicity and tumor heterogeneity.
